Advantame vs Blue Dye 1: which is worse?

What is Advantame?

Advantame is the newest FDA-approved synthetic sweetener, approved in 2014. Like neotame, it is a structural derivative of aspartame but with a vanillin-derived substituent. It is approximately 20,000 times sweeter than sucrose — the most potent sweetener currently approved for food use in the US.

What is Blue Dye 1?

Blue Dye 1 (Brilliant Blue FCF) is a synthetic blue triarylmethane dye derived from petroleum. It produces a brilliant sky-blue color and is highly water-soluble. Unlike the azo dyes (Red 40, Yellow 5/6), Blue 1 belongs to the triarylmethane chemical class.

Documented risks

Advantame: Advantame is the newest approved high-intensity sweetener with the least post-approval safety data. The FDA approval was based on extensive pre-market animal studies showing no significant toxicity, carcinogenicity, reproductive toxicity, or neurotoxicity at relevant doses. EFSA approved it for EU use in 2014, finding no safety concerns based on the submitted data. Like other synthetic sweeteners, advantame has not been studied for long-term effects in large human populations post-approval. The same gut microbiome and glucose tolerance concerns raised for other sweeteners (aspartame, sucralose, acesulfame K) have not been specifically studied for advantame, though the class-wide concerns are relevant. Given its 2014 approval date, independent long-term safety studies are still limited.

Blue Dye 1: Blue Dye 1 was historically banned in several European countries before EU harmonization permitted it (as E133). EFSA's 2010 comprehensive safety re-evaluation found no evidence of carcinogenicity in standard animal tests. The ADI was set at 6 mg/kg body weight. The most significant documented safety concern for Blue 1 involves intravenous/enteral administration rather than dietary intake. In 2003, the FDA issued a Public Health Advisory warning against using Blue 1 (used as a food coloring agent in enteral nutrition formulas to detect aspiration in critically ill patients) after multiple case reports — including deaths — documented that Blue 1 can be absorbed through damaged intestinal mucosa and cause cardiovascular instability, metabolic acidosis, and death. The FDA advisory specifically warned against this clinical use in intensive care patients. This is a medical use concern, not a dietary intake concern. For healthy consumers eating normally, EFSA found no significant safety concerns at food use levels. Blue 1 was not included in the 2007 Lancet hyperactivity study. However, it falls under the FDA's April 2025 announcement to phase out all petroleum-based synthetic food dyes, reflecting updated policy on the class as a whole rather than specific Blue 1 data. Historically, Blue 1 was banned in multiple European countries due to safety concerns, though EU harmonization later permitted it with E-number labeling requirements. This history suggests precautionary concern even when formal regulatory action was not sustained.